Although the regulative effect of most HIF-1a inhibitors on immunosuppressive TME was not determined in clinical and pre-clinical studies, a recent study suggested that these anti-tumor effects of digoxin are at least partially attributed to the decreased recruitment of MDSCs into the TME 16. This evidence concerns the gene HIF1A and neoplasm.